DUBLIN – The contest to develop new therapeutics targeting transforming growth factor beta 1 (TGF-beta1) signaling in cancer intensified this week, as both Abbvie Inc. and Scholar Rock Holding Corp.

A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654 administered daily for 28 days to patients with advanced solid tumors.

MGMT promoter methylation and IDH1 mutation as prognostic markers for a favorable clinical outcome in patients with glioblastoma multiforme. Background: Pseudoprogression (psPD) has frequently been ...

Jefferies initiated coverage of Keros Therapeutics (KROS) with a Buy rating and $107 price target The firm says Keros has expertise in the TGF-beta pathway, which plays roles in blood, lung and muscle ...

ACE-1334 is a TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ACE-1334 ...

Transforming growth factor beta 1 (TGFB1), also known as TGF-β1, CED, DPD1, and TGFB, is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein ...

When it comes to cancer metastasis, it takes two to tango. That was one of the key findings of a new study led by researchers at Memorial Sloan Kettering Cancer Center (MSK): The TGF-beta and RAS ...